NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
NEOGEN CORP
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026
$11.63−0.18 (-1.52%)
Close on Oct 19, 2026
- Market cap
- $2.54B
- P/E (TTM)
- –
- Dividend yield
- –
NEOGEN CORP revenue by segment
By business segment
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Food Safety | $641.10M | $636.10M | $632.20M | $630.89M | $638.10M | $643.25M | $648.20M | $648.37M | $655.30M | $657.70M | $651.49M | $648.43M | 73.7% | +0.5% |
| Animal Safety | $229.30M | $234.48M | $248.18M | $256.06M | $256.60M | $262.75M | $265.60M | $263.81M | $268.90M | $271.53M | $267.19M | $270.65M | 26.3% | -10.6% |
| Operating income | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Food Safety | $63.40M | -$546.13M | -$543.13M | -$996.51M | -$985.70M | -$379.68M | -$383.06M | $78.06M | $82.40M | $81.85M | $76.94M | $74.06M | -106.4% |
| Animal Safety | $24.50M | $17.30M | $18.40M | $9.21M | $7.30M | $17.45M | $25.43M | $33.53M | $39.30M | $38.77M | $34.74M | $39.81M | +235.6% |
By product or service
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product Revenues | $768.20M | $770.14M | $780.44M | $788.99M | $797.40M | $807.92M | $813.60M | $809.92M | $821.80M | $824.73M | $813.24M | $812.69M | 88.3% | -3.7% |
| Service Revenues | $102.20M | $100.44M | $99.94M | $97.96M | $97.30M | $98.08M | $100.21M | $102.26M | $102.40M | $104.51M | $105.44M | $106.40M | 11.7% | +5.0% |
By region
| Revenue | TTM Q4 26 | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $445.30M | $443.27M | $439.97M | $443.21M | $448.70M | $456.10M | $455.08M | $453.66M | $459.00M | $461.36M | $465.11M | $464.65M | 51.2% | -0.8% |
| United States | $425.10M | $427.31M | $440.41M | $443.74M | $446.00M | $449.90M | $458.72M | $458.52M | $465.20M | $467.88M | $453.57M | $454.43M | 48.8% | -4.7% |
From the segment and revenue-disaggregation notes of Neogen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.